Navigation Links
Many Phase 3 Cancer Drug Trials Yield Effective Medicines
Date:3/24/2008

Between a third and a half of these studies bring real clinical improvements, researchers say

MONDAY, March 24 (HealthDay News) -- From 25 percent to 50 percent of new cancer treatments tested in phase 3 randomized clinical trials are eventually found to be effective, say American researchers who analyzed data from 624 phase 3 trials involving more than 216,000 patients.

The trials were all conducted by U.S. National Cancer Institute-funded cooperative groups since 1955.

Dr. Benjamin Djulbegovic, of the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida in Tampa, and colleagues found that 30 percent of the trials had statistically significant results.

In 80 percent of those trials, new treatments were found to be superior to established treatments. The risk-benefit ratio favored new treatments in 41 percent of comparisons, and favored standard treatments in 59 percent of comparisons.

"The real effects of new treatments compared with standard treatments in terms of patient outcomes such as survival is best measured by quantitative pooling of data," the study authors wrote. "When done this way, new treatments are, on average, found to be slightly superior to standard treatments, with a five percent relative reduction in the death rate. This, of course, should not be understood as the average effects of new discoveries being equally spread among all patients."

The researchers also found that breakthrough therapies were discovered in 15 percent of the trials and, in two percent of cases, the breakthroughs reduced the death rate by more than 50 percent.

The study was published in the March 24 issue of the journal Archives of Internal Medicine. Two of the study co-authors received consulting fees and grant support from drug makers Sanofi-Aventis, AMGEN, and Eli Lilly and Company.

"In conclusion, society has received a good return on its investment in the cooperative oncology group system," which funds the trials, the study authors wrote. "The public can expect that about 25 percent to 50 percent of new cancer treatments that reach the stage of assessment in clinical trials will prove to be successful. This pattern of successes has become more consistent over time. However, our results also indicate that the absolute number of discoveries might be improved if the proportion of inconclusive trials is reduced."

Cancer is the second leading cause of death in the United States. Over the years, there have been continuous improvements made in survival and other outcomes, in large part due to the introduction of new treatments tested in clinical trials, according to background information in the study.

More information

The U.S. National Cancer Institute has more about cancer clinical trials.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, March 24, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Cancer treatments in phase 3 trials successful up to half of the time
2. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
3. MGH initiates phase I diabetes trial
4. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
5. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
6. Akela Pharma initiates its first abuse deterrent opioid Phase I clinical trial
7. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
8. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
9. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
10. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
11. Positive results from phase 1 clinical trials of cuprindro
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Many Phase 3 Cancer Drug Trials Yield Effective Medicines
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State University ... to 20. , The two-day conference is focused on advancing scientific knowledge about ... patients’ lives and eliminating racial breast cancer-related disparities. The conference theme is “Illuminating ...
(Date:6/23/2017)... ... June 23, 2017 , ... American Farmer, will feature ... which is slated to air fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET ... a Danish pharmacist, founded Chr. Hansen in Denmark in 1874 after a groundbreaking discovery ...
(Date:6/23/2017)... Morgantown, WV (PRWEB) , ... June 23, 2017 ... ... asset protection services and personal financial planning to families and business owners in ... Stepping Stones organization to help provide services to differently abled residents in the ...
(Date:6/22/2017)... ... ... Groove Ring is excited to announce they've partnered with Olympic runner Jared ... all-purpose rings. Whether you’re an athlete, adventurer, professional, or love to venture the great ... the rock face to the auto shop, Groove Ring is the world's first breathable ...
(Date:6/22/2017)... Angeles, California (PRWEB) , ... June 22, 2017 , ... ... therapist Nira Rittenberg to a correspondent concerned about an apparent lack of oral hygiene ... Rittenberg, who specializes in geriatrics and dementia-related matters, suggests a number of steps, including ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:5/30/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will present ... Conference on Tuesday, June 13, 2017, in Rancho ... president and chief executive officer, is scheduled to present at ... can be accessed at http://ir.hill-rom.com/events.cfm . A recorded replay ... event through September 13, 2017. ...
(Date:5/24/2017)...  ivWatch LLC today announced the launch of ... enable seamless integration of ivWatch,s groundbreaking IV infiltration ... and other devices. By integrating ivWatch technology into ... health care customers deliver a higher level of ... therapy. "The ivWatch OEM Board provides ...
Breaking Medicine Technology: